In ONdrugDelivery, Nanexa’s Anders Johansson, Polla Rouf and Oliver Hedge outline how the company’s PharmaShell ALD nanocoating technology is enabling once‑monthly — and potentially once‑quarterly — injectable therapies. The authors explain how ultra‑thin, inorganic ALD coatings applied to drug microparticles create highly controlled depot formulations that dissolve at a tuned rate, delivering steady drug release over weeks to months. By avoiding polymer‑based systems and their unpredictable burst‑and‑tail behaviour, PharmaShell achieves flatter pharmacokinetic profiles, reduced peak‑related side effects and significantly lower dosing frequency.

The article highlights Nanexa’s progress with long‑acting GLP‑1 therapies, including a once‑monthly semaglutide depot supported by preclinical data and earlier clinical proof‑of‑concept from a PharmaShell‑coated liraglutide study. Recent formulation advances have produced near‑linear 30‑day release, improved tolerability and a ready‑to‑use suspension compatible with fine‑gauge needles and autoinjectors. With scale‑up plans underway and device integration progressing, the authors position PharmaShell as a next‑generation delivery platform capable of transforming chronic disease management through smarter, ultra‑long‑acting injectables.

Read the full article here.